Tissue hypoxia, inflammation, and loss of glomerular filtration rate in human atherosclerotic renovascular disease.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
04 2019
Historique:
received: 04 09 2018
revised: 15 11 2018
accepted: 29 11 2018
entrez: 25 3 2019
pubmed: 25 3 2019
medline: 15 2 2020
Statut: ppublish

Résumé

The relationships between renal blood flow (RBF), tissue oxygenation, and inflammatory injury in atherosclerotic renovascular disease (ARVD) are poorly understood. We sought to correlate RBF and tissue hypoxia with glomerular filtration rate (GFR) in 48 kidneys from patients with ARVD stratified by single kidney iothalamate GFR (sGFR). Oxygenation was assessed by blood oxygenation level dependent magnetic resonance imaging (BOLD MRI), which provides an index for the levels of deoxyhemoglobin within a defined volume of tissue (R2*). sGFR correlated with RBF and with the severity of vascular stenosis as estimated by duplex velocities. Higher cortical R2* and fractional hypoxia and higher levels of renal vein neutrophil-gelatinase-associated-lipocalin (NGAL) and monocyte-chemoattractant protein-1 (MCP-1) were observed at lower GFR, with an abrupt inflection below 20 ml/min. Renal vein MCP-1 levels correlated with cortical R2* and with fractional hypoxia. Correlations between cortical R2* and RBF in the highest sGFR stratum (mean sGFR 51 ± 12 ml/min; R = -0.8) were degraded in the lowest sGFR stratum (mean sGFR 8 ± 3 ml/min; R = -0.1). Changes in fractional hypoxia after furosemide were also absent in the lowest sGFR stratum. These data demonstrate relative stability of renal oxygenation with moderate reductions in RBF and GFR but identify a transition to overt hypoxia and inflammatory cytokine release with severely reduced GFR. Tissue oxygenation and RBF were less correlated in the setting of reduced sGFR, consistent with variable oxygen consumption or a shift to alternative mechanisms of tissue injury. Identifying transitions in tissue oxygenation may facilitate targeted therapy in ARVD.

Identifiants

pubmed: 30904069
pii: S0085-2538(19)30031-6
doi: 10.1016/j.kint.2018.11.039
pmc: PMC6738340
mid: NIHMS1519409
pii:
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Clinical Trial, Phase I Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

948-957

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK109134
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK118120
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK100081
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL085307
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK073608
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL098967
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024150
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK102325
Pays : United States

Informations de copyright

Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Références

Kidney Int Suppl. 2000 Apr;75:S22-6
pubmed: 10828757
Nature. 1992 Oct 29;359(6398):843-5
pubmed: 1279431
J Magn Reson Imaging. 2005 Sep;22(3):347-53
pubmed: 16104014
J Am Soc Nephrol. 2008 Apr;19(4):780-8
pubmed: 18287564
Am J Physiol Renal Physiol. 2008 Nov;295(5):F1259-70
pubmed: 18550645
Am J Physiol Regul Integr Comp Physiol. 2009 Jan;296(1):R67-71
pubmed: 18971350
Circulation. 2009 Feb 3;119(4):547-57
pubmed: 19153272
Curr Opin Nephrol Hypertens. 2009 Mar;18(2):160-5
pubmed: 19430335
N Engl J Med. 2009 Nov 12;361(20):1953-62
pubmed: 19907042
Nephrol Dial Transplant. 2010 Apr;25(4):1133-40
pubmed: 20028827
Hypertension. 2010 Apr;55(4):961-6
pubmed: 20194303
Clin Exp Pharmacol Physiol. 2011 Apr;38(4):247-54
pubmed: 21306412
Hypertension. 2011 Dec;58(6):1066-72
pubmed: 22042812
Kidney Int. 2012 Apr;81(7):684-9
pubmed: 22237750
Stem Cells. 2012 May;30(5):1030-41
pubmed: 22290832
Adv Exp Med Biol. 2013;765:329-334
pubmed: 22879052
Kidney Int. 2012 Oct;82(8):934; author reply 935
pubmed: 23018827
Radiology. 2013 Sep;268(3):770-8
pubmed: 23788716
Circ Cardiovasc Interv. 2013 Aug;6(4):428-35
pubmed: 23899868
Hypertension. 2013 Nov;62(5):914-9
pubmed: 24019401
Cardiovasc Res. 2014 Sep 1;103(4):461-72
pubmed: 24947415
Int J Nephrol Renovasc Dis. 2014 Nov 21;7:421-35
pubmed: 25473304
Radiology. 2015 Aug;276(2):490-8
pubmed: 25848903
J Am Soc Nephrol. 2015 Sep;26(9):2074-80
pubmed: 25868641
J Am Soc Nephrol. 2016 Jun;27(6):1741-52
pubmed: 26541349
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):458-69
pubmed: 26787779
Nephrol Dial Transplant. 2016 Sep;31(9):1437-43
pubmed: 26908767
Am J Nephrol. 2016;44(5):354-367
pubmed: 27771702
Front Physiol. 2017 Jan 05;7:667
pubmed: 28105019
Nephrol Dial Transplant. 2017 Feb 1;32(2):307-315
pubmed: 28186566
Front Physiol. 2017 Feb 21;8:99
pubmed: 28270773
J Am Soc Nephrol. 2017 Sep;28(9):2777-2785
pubmed: 28461553
Radiology. 2018 Jan;286(1):129-139
pubmed: 28777704
Am J Hypertens. 2018 Jan 12;31(2):139-149
pubmed: 28985335
Kidney Int. 2018 Apr;93(4):932-940
pubmed: 29325997
J Cardiovasc Comput Tomogr. 2018 Mar - Apr;12(2):149-152
pubmed: 29339048
Kidney Int. 2018 Apr;93(4):778-780
pubmed: 29571450
Sci Rep. 2018 Jun 5;8(1):8598
pubmed: 29872089
Circulation. 1996 Dec 15;94(12):3271-5
pubmed: 8989140
Kidney Int. 1997 Feb;51(2):372-80
pubmed: 9027709
Kidney Int. 1997 Feb;51(2):381-5
pubmed: 9027710
Am J Kidney Dis. 1997 Nov;30(5):646-52
pubmed: 9370179

Auteurs

Abdelrhman Abumoawad (A)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

Ahmed Saad (A)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Department of Family Medicine, Creighton University, Omaha, Nebraska, USA.

Christopher M Ferguson (CM)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

Alfonso Eirin (A)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

John R Woollard (JR)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

Sandra M Herrmann (SM)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

LaTonya J Hickson (LJ)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

Emily C Bendel (EC)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Sanjay Misra (S)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

James Glockner (J)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Lilach O Lerman (LO)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

Stephen C Textor (SC)

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: stextor@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH